quindoxin has been researched along with Carcinoma, Lewis Lung in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Hmaira, J; Gali-Muhtasib, H; Geara, F; Haddadin, MJ; Mona, AD; Sidani, M; Zaatari, G | 1 |
1 other study(ies) available for quindoxin and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Lewis Lung; Cell Hypoxia; Cell Survival; Collagen; Combined Modality Therapy; Drug Combinations; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Laminin; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Necrosis; Neovascularization, Pathologic; Proteoglycans; Quinoxalines; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A | 2004 |